Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger

The transaction is expected to result in approximately $175 million to support further development of IMG-007

Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype

Lilly and EVA Pharma collaborate to expand access to baricitinib across 49 low- to middle-income countries in Africa

Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases

Glenmark partners Pfizer to launch Abrocitinib in India

Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India

Ichnos Sciences inks agreement with Astria Therapeutics for OX40 antagonist monoclonal antibody portfolio

Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications

Lilly's Lebrikizumab shows improved face or hand dermatitis

Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients

Top 20 global biopharma companies report 3.4% fall in market cap in Q1 2023: GlobalData

Bayer reported the highest market capitalization growth of 23.1% during Q1 2023

FDA approves Pfizer's supplemental new drug application for CIBINQO

Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis

Strong execution in Q2 drives full-year 2022 guidance upgrade for Sanofi

Syngene signs 10-year biologics manufacturing agreement with Zoetis

Syngene's collaboration with Zoetis started in 2011